Innoventric
Pioneering transcatheter technology for tricuspid regurgitation with a novel cross-caval approach.
About
Technology stack
detected 2026-06-17No comments yet. Be the first to share your take.
What does Innoventric do?
Innoventric is a medical device company specializing in a novel transcatheter cross-caval approach for treating tricuspid regurgitation (TR). Their Unica™ implant offers a simple, anatomy-agnostic solution designed for safe and effective TR treatment, aiming to expand care to a broader patient population. The company is focused on advancing this technology through clinical trials and has secured significant funding to support its development.
How much funding has Innoventric raised?
Innoventric has raised a total of $49M in funding. The most recent round on record is Series B.
Where is Innoventric headquartered?
Innoventric is headquartered in San Jose, United States.
When was Innoventric founded?
Innoventric was founded in 2016.
What industry does Innoventric operate in?
Innoventric operates in Healthcare, Medical Devices, Cardiology, Innovation, Biotechnology, MedTech.
How many employees does Innoventric have?
Innoventric has approximately 23 people on record.